市場調査レポート

商品コード

生物製剤の世界市場、2030年までの予測：製品別、タイプ別、用途別、地域別の世界分析

Biologic Therapeutics Market Forecasts to 2030 - Global Analysis By Product (Gene Therapy, Cell Therapy, Vaccines, Antibody Therapeutics and Other Products), Type, Application and By Geography

出版日: 2023年10月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 609,303円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 770,805円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 932,307円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,101,150円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の生物製剤市場は、2023年に4,575億6,000万米ドルを占め、2030年には11.3%のCAGRで成長し、9,680億8,000万米ドルに達すると予測されています。

生物学的供給源から生成される治療薬の開発、生産、マーケティングに集中する製薬産業部門は、生物製剤市場と呼ばれます。これらの複雑な化学薬品は、タンパク質、抗体、核酸、細胞など、生体またはその一部を用いて作られます。生物製剤または生物医薬品とも呼ばれます。

世界保健機関（WHO）によると、ワクチンは世界の疾病負担を軽減する最も強力で費用対効果の高い方法のひとつであり、毎年200万～300万人の命を救うと推定されています。

加齢に伴う慢性疾患の増加と生物製剤のパイプラインの拡大

がん、自己免疫疾患、代謝性疾患のような慢性疾患の増加により、効率的な代替治療の必要性が高まっています。生物製剤は、多くの疾患の根本原因に対処できる、カスタマイズされた標的治療を提供し、市場の拡大に拍車をかけています。さらに、生物製剤の開発は製薬業界やバイオテクノロジー業界から多額の資金援助を受けています。組換えタンパク質、細胞・遺伝子治療、モノクローナル抗体などの生物製剤の開発は市場を活性化し、技術革新に拍車をかけています。

開発・生産、製造、サプライチェーン・マネジメントのコストが高く、非常に複雑です。

生物製剤の開発・製造には、研究開発、臨床試験、製造施設など、複雑な手続きと多額の費用がかかります。特に資源が限られているヘルスケアシステムでは、このような高コストが生物製剤の入手可能性と購入可能性を制限する可能性があります。しかし、生物製剤はその複雑な性質から、専門的な製造施設や製造手順を必要とします。一貫した品質やスケーラビリティを確保し、強固なサプライチェーンを維持することは困難であり、生物製剤による治療へのアクセスや購入のしやすさに影響を及ぼす可能性があります。

バイオテクノロジーと遺伝子工学の進歩と有利な規制状況

バイオテクノロジー、遺伝子工学、組換えDNA技術の進展により、革新的な生物学的療法を生み出す可能性が高まっています。これらの技術開発により、より洗練され、特異的に標的を絞った生物学的薬剤の生産が可能になり、利用可能な治療法の数が拡大しています。さらに、欧州医薬品庁（EMA）や米国食品医薬品局（FDA）をはじめとする規制機関は、生物製剤の承認について正確な規則を定め、迅速な承認手続きを確立しています。これらの規制体制は、生物製剤の開発、評価、販売に有利な環境を提供しています。

高水準の規制と免疫原性・安全性への懸念

有利な規制の枠組みが存在するにもかかわらず、生物製剤の承認手続きは複雑で厳しいです。安全性、有効性、品質を証明するために企業が実施しなければならない大規模な前臨床試験や臨床試験には、長い時間と多額の費用がかかります。しかし、生物学的療法に対する患者の免疫応答が誘導される可能性があり、その安全性と免疫原性に懸念が生じる。治療の有効性と安全性は、このような免疫学的反応によって影響を受ける可能性があり、その程度は様々です。生物学的治療を効果的に使用するためには、このような問題の効果的なモニタリングと管理を行うことが極めて重要です。

COVID-19の影響

COVID-19の流行により、効率的な予防接種の作成と配布が不可欠となっています。その結果、mRNAやウイルスベクターベースのワクチンのような生物学的プラットフォームを利用したワクチンの研究開発が大幅に増加しました。COVID-19ワクチンの効果的な作成と応用は、生物学的治療の有望性を浮き彫りにし、感染症対策におけるバイオテクノロジー分野の重要性を強調しました。

予測期間中、血液製剤分野が最大となる見込み

予測期間中、最大のシェアを占めたのは血液製剤分野でした。免疫グロブリン、凝固因子、血漿由来タンパク質を含む血液由来製品は、様々な血液疾患や免疫不全の治療に使用されており、生物学的療法の一部とも考えられています。これらの品目の使用は、多くの血液疾患、免疫不全、その他の病気の管理に不可欠です。

予測期間中にCAGRが最も高くなると予想されるのは細胞療法分野です。

細胞治療分野は、予測期間中に有利な成長を遂げると推定されます。生きた細胞は、病気の治療や治癒のために細胞治療に使用されます。細胞療法は、損傷したり病気になったりした細胞や組織を置換、修復、修復しようとする、急速に発展している分野です。さらに、細胞療法は、腫瘍学、心血管疾患、神経変性疾患、自己免疫疾患など、多くの治療分野で可能性を示しています。

最大のシェアを占める地域

アジア太平洋地域は、生物学的療法産業が大幅な発展と革新を遂げ、活気があり急速に変化するハブとして台頭していることから、予測期間中に最大のシェアを占めると予想されます。この地域は、独自のヘルスケアシステムを持つ多くの国とつながっており、複雑でありながら魅力的な市場となっています。さらに、がん、糖尿病、自己免疫疾患などの慢性疾患の蔓延により、生物学的治療に対するニーズが高まっています。

CAGRが最も高い地域

アジア太平洋のCAGRが最も高いと推定されます。中間所得層の拡大とヘルスケアコストの上昇により、生物学的療法の利用可能性が拡大しています。これは、ヘルスケア・インフラの建設を奨励する政府の政策とともに、市場の成長をさらに後押ししています。さらに、アジア太平洋では研究開発活動が活況を呈しており、国内外の製薬企業が生物製剤の開発に多額の投資を行っています。バイオテクノロジーの生態系が盛んなため、人材が集まり、イノベーションが促進される結果となっています。この地域の政府も承認手続きの簡素化に努めており、バイオ医薬品企業の市場参入のしやすさを向上させています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

企業プロファイル
- 追加市場企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的存在、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他のアジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他の南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他の中東・アフリカ

第9章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第10章企業プロファイル

AbbVie Inc
Amgen Inc.
AstraZeneca Plc
Aurobindo Pharma Ltd.
Baxter International Inc
Biocon Ltd.
Celltrion Healthcare Co. Ltd.
GlaxoSmithKline Plc
Merck and Co. Inc
Novartis AG
Pfizer Inc
Precision Biologics Inc
Samsung Electronics Co. Ltd

図表

List of Tables

Table 1 Global Biologic Therapeutics Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 3 Global Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
Table 4 Global Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
Table 5 Global Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
Table 6 Global Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
Table 7 Global Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 8 Global Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
Table 9 Global Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
Table 10 Global Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
Table 11 Global Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
Table 12 Global Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
Table 13 Global Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
Table 14 Global Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
Table 15 Global Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
Table 16 Global Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
Table 17 Global Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
Table 18 Global Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
Table 19 Global Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
Table 20 North America Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 21 North America Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 22 North America Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
Table 23 North America Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
Table 24 North America Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
Table 25 North America Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
Table 26 North America Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 27 North America Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
Table 28 North America Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
Table 29 North America Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
Table 30 North America Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
Table 31 North America Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
Table 32 North America Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
Table 33 North America Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
Table 34 North America Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
Table 35 North America Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
Table 36 North America Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
Table 37 North America Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
Table 38 North America Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
Table 39 Europe Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 40 Europe Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 41 Europe Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
Table 42 Europe Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
Table 43 Europe Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
Table 44 Europe Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
Table 45 Europe Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 46 Europe Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
Table 47 Europe Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
Table 48 Europe Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
Table 49 Europe Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
Table 50 Europe Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
Table 51 Europe Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
Table 52 Europe Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
Table 53 Europe Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
Table 54 Europe Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
Table 55 Europe Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
Table 56 Europe Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
Table 57 Europe Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
Table 58 Asia Pacific Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 59 Asia Pacific Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 60 Asia Pacific Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
Table 61 Asia Pacific Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
Table 62 Asia Pacific Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
Table 63 Asia Pacific Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
Table 64 Asia Pacific Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 65 Asia Pacific Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
Table 66 Asia Pacific Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
Table 67 Asia Pacific Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
Table 68 Asia Pacific Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
Table 69 Asia Pacific Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
Table 70 Asia Pacific Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
Table 71 Asia Pacific Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
Table 72 Asia Pacific Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
Table 73 Asia Pacific Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
Table 74 Asia Pacific Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
Table 75 Asia Pacific Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
Table 76 Asia Pacific Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
Table 77 South America Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 78 South America Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 79 South America Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
Table 80 South America Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
Table 81 South America Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
Table 82 South America Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
Table 83 South America Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 84 South America Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
Table 85 South America Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
Table 86 South America Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
Table 87 South America Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
Table 88 South America Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
Table 89 South America Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
Table 90 South America Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
Table 91 South America Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
Table 92 South America Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
Table 93 South America Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
Table 94 South America Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
Table 95 South America Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
Table 96 Middle East & Africa Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
Table 97 Middle East & Africa Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
Table 98 Middle East & Africa Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
Table 99 Middle East & Africa Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
Table 100 Middle East & Africa Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
Table 101 Middle East & Africa Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
Table 102 Middle East & Africa Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
Table 103 Middle East & Africa Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
Table 104 Middle East & Africa Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
Table 105 Middle East & Africa Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
Table 106 Middle East & Africa Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
Table 107 Middle East & Africa Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
Table 108 Middle East & Africa Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
Table 109 Middle East & Africa Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
Table 110 Middle East & Africa Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
Table 111 Middle East & Africa Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
Table 112 Middle East & Africa Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
Table 113 Middle East & Africa Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
Table 114 Middle East & Africa Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)

Product Code: SMRC23948

According to Stratistics MRC, the Global Biologic Therapeutics Market is accounted for $457.56 billion in 2023 and is expected to reach $968.08 billion by 2030 growing at a CAGR of 11.3% during the forecast period. The pharmaceutical industry sector that concentrates on the development, production, and marketing of therapeutic medicines generated from biological sources is referred to as the biologic therapeutics market. These complex chemicals are created using living organisms or their parts, such as proteins, antibodies, nucleic acids, or cells. They are also referred to as biologics or biological pharmaceuticals.

According to World Health Organization, vaccines are one of the most powerful and cost-effective ways to reduce the global burden of disease and are estimated to save 2-3 million lives every year.

Market Dynamics:

Driver:

Increasing prevalence of age-related and chronic diseases and expanding pipeline of biologics

The need for efficient treatment alternatives is being driven by the increased prevalence of chronic diseases like cancer, autoimmune conditions, and metabolic diseases. Biologic medicines provide customized, targeted treatments that can address the underlying causes of many disorders, spurring market expansion. Additionally, the development of biologic medicines has received significant funding from the pharmaceutical and biotechnology industries. Biologic medication development, including recombinant proteins, cell and gene therapies, and monoclonal antibodies, is boosting the market and spurring innovation.

Restraint:

High costs of development and production, manufacturing and supply chain management are quite complex

Complex procedures and high expenditures, such as those associated with research and development, clinical trials, and manufacturing facilities, are involved in the creation and production of biologic therapies. Particularly in healthcare systems with limited resources, these high costs may restrict the availability and affordability of biologic medications. However, due to their complicated nature, biologic pharmaceuticals need specialized production facilities and procedures. It can be difficult to ensure consistent quality, scaleability, and maintain a strong supply chain, which may have an impact on the accessibility and affordability of biologic treatments.

Opportunity:

Biotechnology and genetic engineering advancements and favorable regulatory landscape

The potential for creating innovative biological therapies has increased as a result of ongoing developments in biotechnology, genetic engineering, and recombinant DNA technology. These technological developments make it possible to produce biological medications that are more sophisticated and specifically targeted, expanding the number of available treatments. Additionally, regulatory organizations have established precise rules and accelerated paths for the approval of biologic therapies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). These regulatory regimes offer a favorable environment for the creation, assessment, and marketing of biologic medicines.

Threat:

High standards of regulation and concerns about immunogenicity and safety

Despite the existence of favorable regulatory frameworks, the complex and stringent approval procedures for biologic therapies. Extensive preclinical and clinical trials that must be conducted by companies to prove safety, efficacy, and quality can take a long time and cost a lot of funds. However, patients' immune responses to biological therapies may be induced, raising concerns regarding their safety and immunogenicity. The effectiveness and safety of the treatment may be impacted by these immunological reactions, which can range in severity. For biological treatments to be used effectively, it is crucial to provide effective monitoring and management of these problems.

COVID-19 Impact:

The COVID-19 epidemic made the creation and distribution of efficient vaccinations essential. As a result, vaccine research and development significantly increased, utilizing biological platforms like mRNA and viral vector-based vaccines. The effective creation and application of COVID-19 vaccines highlighted the promise of biological treatments and emphasized the significance of the biotechnology sector in combating infectious diseases.

The blood products segment is expected to be the largest during the forecast period

Blood products segment commanded the largest share over the forecast period. Blood-derived products, including immunoglobulins, clotting factors, and plasma-derived proteins, which are used to treat a variety of blood illnesses and immunological deficiencies, are also considered to be part of biologic therapies. The use of these items is essential in the management of a number of blood diseases, immunological deficiencies, and other ailments.

The cell therapy segment is expected to have the highest CAGR during the forecast period

Cell therapy segment is estimated to witness lucrative growth over the projection period. Living cells are used in cell therapy to treat or cure diseases. It is a fast-developing area that seeks to replace, restore, or fix damaged or sick cells or tissues. Additionally, cell therapy has demonstrated potential in a number of therapeutic fields, including oncology, cardiovascular illness, neurodegenerative disorders, and autoimmune diseases.

Region with largest share:

Asia Pacific is expected to hold largest share over the forecast period as the biological therapies industry experiences substantial development and innovation, the Asia-Pacific region is emerging as a vibrant and quickly changing hub. This region is connected to numerous nations with distinctive healthcare systems, making it a complex yet attractive market. Additionally, the region's growing need for biological treatments is being driven by the prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders.

Region with highest CAGR:

Asia Pacific is estimated to hold highest CAGR. The availability of biological therapies has expanded as a result of an expanding middle-class population and rising healthcare costs. This has further propelled the market's growth, along with government policies to encourage the construction of healthcare infrastructure. Additionally, the Asia-Pacific region is experiencing a boom in research and development activity, with both domestic and foreign pharmaceutical firms making significant investments in the development of biologic drugs. A thriving biotechnology ecosystem has resulted in an outcome that draws in talent and encourages innovation. Governments in the area are also making efforts to simplify approval procedures, improving the simplicity of market access for biopharmaceutical firms.

Key players in the market:

Some of the key players in Biologic Therapeutics Market include: AbbVie Inc, Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc, Biocon Ltd., Celltrion Healthcare Co. Ltd., GlaxoSmithKline Plc, Merck and Co. Inc, Novartis AG, Pfizer Inc , Precision Biologics Inc and Samsung Electronics Co. Ltd.

Key Developments:

In May 2022, Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, announceD the launch of its new CRYOcheck Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities. The announcement was made at the World Federation of Hemophilia Congress taking place in Montreal

Products Covered:

Gene Therapy
Cell Therapy
Vaccines
Antibody Therapeutics
Other Products

Types Covered:

Allergenic Extracts
Blood Products
Human Cells and Tissues
Protein
Xenotransplantation Products
Other Types

Applications Covered:

Autoimmune Diseases
Infectious Diseases
Cancer
Other Applications

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Biologic Therapeutics Market, By Product

5.1 Introduction
5.2 Gene Therapy
5.3 Cell Therapy
5.4 Vaccines
5.5 Antibody Therapeutics
5.6 Other Products

6 Global Biologic Therapeutics Market, By Type

6.1 Introduction
6.2 Allergenic Extracts
6.3 Blood Products
6.4 Human Cells and Tissues
6.5 Protein
6.6 Xenotransplantation Products
6.7 Other Types

7 Global Biologic Therapeutics Market, By Application

7.1 Introduction
7.2 Autoimmune Diseases
7.3 Infectious Diseases
7.4 Cancer
7.5 Other Applications

8 Global Biologic Therapeutics Market, By Geography

8.1 Introduction
8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling

10.1 AbbVie Inc
10.2 Amgen Inc.
10.3 AstraZeneca Plc
10.4 Aurobindo Pharma Ltd.
10.5 Baxter International Inc
10.6 Biocon Ltd.
10.7 Celltrion Healthcare Co. Ltd.
10.8 GlaxoSmithKline Plc
10.9 Merck and Co. Inc
10.10 Novartis AG
10.11 Pfizer Inc
10.12 Precision Biologics Inc
10.13 Samsung Electronics Co. Ltd